Drug intelligence / Profile preview

APVO452

Development stage: Preclinical
Lead developer: Aptevo Therapeutics
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

APVO452 is a trispecific immune cell engager biologic developed by Aptevo Therapeutics utilizing its proprietary ADAPTIR-FLEX™ platform. It is engineered to target prostate cancer by simultaneously binding to Prostate-Specific Membrane Antigen (PSMA) on tumor cells, CD3 on T cells to activate them, and CD40 to modulate immunosuppressive cells within the tumor microenvironment. This multi-pronged mechanism aims to achieve potent and durable anti-tumor responses while minimizing systemic toxicity.

Targets

CD40 (Cluster of differentiation 40 receptor)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on APVO452.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APVO452.

Explore the full profile